CorMedix Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.
No three-year revenue growth on file: 5% to start with.
US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt or cash not on file: 0 to start with.
What today's price assumes
A market value of $652 M means free cash flow growing 9.7% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | 0% | 2.5% | 5% | 7.5% | 10% |
|---|---|---|---|---|---|
| 7.92% | -34% | -19% | -2% | +19% | +45% |
| 8.92% | -44% | -32% | -18% | -1% | +20% |
| 9.92% | -51% | -41% | -29% | -15% | +2% |
| 10.92% | -56% | -48% | -38% | -26% | -12% |
| 11.92% | -61% | -54% | -45% | -35% | -22% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of CorMedix Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Biotechnology
Multiples of its companies with a market value at most 60 days old, times CorMedix Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | CorMedix Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| P/E | 9.4× / 20.3× / 59.0× | 10.2× | net income $163 M | $1.5 B to $9.6 B | 33 |
| Price to sales | 2.3× / 5.0× / 10.2× | 1.6× | revenue $312 M | $701 M to $3.2 B | 84 |
| Price to book | 3.2× / 4.6× / 12.9× | 1.6× | book equity $405 M | $1.3 B to $5.2 B | 69 |
Against its own history
CorMedix Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
P/E
3.5×Now below its median of 3.8×; range 3.1× to 56.8× over 18 months.
Price to sales
1.4×Now below its median of 1.8×, in the bottom quarter of its range; range 1.3× to 894.7× over 15 months.
Price to book
1.6×Now below its median of 7.2×, in the bottom quarter of its range; range 1.3× to 36.5× over 30 months.
As of Oct 29, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $312 M | $163 M | $175 M | $2 M | $173 M | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $43 M | $-18 M | $-51 M | $0 M | $-51 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | — | $-46 M | $-38 M | $0 M | $-39 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $0 M | $-30 M | $-24 M | $0 M | $-25 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $0 M | $-28 M | $-21 M | $1 M | $-23 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $0 M | $-22 M | $-22 M | $0 M | $-22 M | — | SEC annual report (10-K, 20-F) |